296 related articles for article (PubMed ID: 31403473)
21. Characterization of Gut Microbiota in Hospitalized Patients with Clostridioides difficile Infection.
Vakili B; Fateh A; Asadzadeh Aghdaei H; Sotoodehnejadnematalahi F; Siadat SD
Curr Microbiol; 2020 Aug; 77(8):1673-1680. PubMed ID: 32296918
[TBL] [Abstract][Full Text] [Related]
22.
Battaglioli EJ; Hale VL; Chen J; Jeraldo P; Ruiz-Mojica C; Schmidt BA; Rekdal VM; Till LM; Huq L; Smits SA; Moor WJ; Jones-Hall Y; Smyrk T; Khanna S; Pardi DS; Grover M; Patel R; Chia N; Nelson H; Sonnenburg JL; Farrugia G; Kashyap PC
Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355801
[TBL] [Abstract][Full Text] [Related]
23. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
24.
Jenior ML; Leslie JL; Young VB; Schloss PD
mSphere; 2018 Jun; 3(3):. PubMed ID: 29950381
[TBL] [Abstract][Full Text] [Related]
25. Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection.
Henson MA
PLoS Comput Biol; 2021 Feb; 17(2):e1008782. PubMed ID: 33617526
[TBL] [Abstract][Full Text] [Related]
26. Microbe-microbe interactions during Clostridioides difficile infection.
Abbas A; Zackular JP
Curr Opin Microbiol; 2020 Feb; 53():19-25. PubMed ID: 32088581
[TBL] [Abstract][Full Text] [Related]
27. Analysis of Intestinal Mycobiota of Patients with Clostridioides difficile Infection among a Prospective Inpatient Cohort.
Cao Y; Wang L; Ke S; Kelly CP; Pollock NR; Villafuerte Gálvez JA; Daugherty K; Xu H; Yao J; Chen Y; Liu YY; Chen X
Microbiol Spectr; 2022 Aug; 10(4):e0136222. PubMed ID: 35867408
[TBL] [Abstract][Full Text] [Related]
28. Fecal Mycobiota Combined With Host Immune Factors Distinguish Clostridioides difficile Infection From Asymptomatic Carriage.
Cao Y; Wang L; Ke S; Villafuerte Gálvez JA; Pollock NR; Barrett C; Sprague R; Daugherty K; Xu H; Lin Q; Yao J; Chen Y; Kelly CP; Liu YY; Chen X
Gastroenterology; 2021 Jun; 160(7):2328-2339.e6. PubMed ID: 33684427
[TBL] [Abstract][Full Text] [Related]
29. Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile.
Yoon S; Yu J; McDowell A; Kim SH; You HJ; Ko G
J Microbiol; 2017 Nov; 55(11):892-899. PubMed ID: 29076071
[TBL] [Abstract][Full Text] [Related]
30. Strain-Dependent Inhibition of Clostridioides difficile by Commensal
Reed AD; Nethery MA; Stewart A; Barrangou R; Theriot CM
J Bacteriol; 2020 May; 202(11):. PubMed ID: 32179626
[No Abstract] [Full Text] [Related]
31. Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.
Stone NE; Nunnally AE; Jimenez V; Cope EK; Sahl JW; Sheridan K; Hornstra HM; Vinocur J; Settles EW; Headley KC; Williamson CHD; Rideout JR; Bolyen E; Caporaso JG; Terriquez J; Monroy FP; Busch JD; Keim P; Wagner DM
Anaerobe; 2019 Aug; 58():53-72. PubMed ID: 30946985
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of Colonization Resistance Against Clostridioides difficile.
Pike CM; Theriot CM
J Infect Dis; 2021 Jun; 223(12 Suppl 2):S194-S200. PubMed ID: 33326565
[TBL] [Abstract][Full Text] [Related]
33. Composition of gut microbiota in patients with toxigenic Clostridioides (Clostridium) difficile: Comparison between subgroups according to clinical criteria and toxin gene load.
Han SH; Yi J; Kim JH; Lee S; Moon HW
PLoS One; 2019; 14(2):e0212626. PubMed ID: 30785932
[TBL] [Abstract][Full Text] [Related]
34. An Integrated Metabolomic and Microbiome Analysis Identified Specific Gut Microbiota Associated with Fecal Cholesterol and Coprostanol in Clostridium difficile Infection.
Antharam VC; McEwen DC; Garrett TJ; Dossey AT; Li EC; Kozlov AN; Mesbah Z; Wang GP
PLoS One; 2016; 11(2):e0148824. PubMed ID: 26871580
[TBL] [Abstract][Full Text] [Related]
35. Microbiota-based markers predictive of development of Clostridioides difficile infection.
Berkell M; Mysara M; Xavier BB; van Werkhoven CH; Monsieurs P; Lammens C; Ducher A; Vehreschild MJGT; Goossens H; de Gunzburg J; Bonten MJM; Malhotra-Kumar S;
Nat Commun; 2021 Apr; 12(1):2241. PubMed ID: 33854066
[TBL] [Abstract][Full Text] [Related]
36. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.
Allegretti JR; Kearney S; Li N; Bogart E; Bullock K; Gerber GK; Bry L; Clish CB; Alm E; Korzenik JR
Aliment Pharmacol Ther; 2016 Jun; 43(11):1142-53. PubMed ID: 27086647
[TBL] [Abstract][Full Text] [Related]
37. Risk factors and intestinal microbiota: Clostridioides difficile infection in patients receiving enteral nutrition at Intensive Care Units.
Wang D; Dong D; Wang C; Cui Y; Jiang C; Ni Q; Su T; Wang G; Mao E; Peng Y
Crit Care; 2020 Jul; 24(1):426. PubMed ID: 32660525
[TBL] [Abstract][Full Text] [Related]
38. Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population.
Gu S; Chen Y; Zhang X; Lu H; Lv T; Shen P; Lv L; Zheng B; Jiang X; Li L
Microbes Infect; 2016 Jan; 18(1):30-8. PubMed ID: 26383014
[TBL] [Abstract][Full Text] [Related]
39. Gut metabolites predict Clostridioides difficile recurrence.
Dawkins JJ; Allegretti JR; Gibson TE; McClure E; Delaney M; Bry L; Gerber GK
Microbiome; 2022 Jun; 10(1):87. PubMed ID: 35681218
[TBL] [Abstract][Full Text] [Related]
40. Tauroursodeoxycholic Acid Inhibits Clostridioides difficile Toxin-Induced Apoptosis.
Pike CM; Tam J; Melnyk RA; Theriot CM
Infect Immun; 2022 Aug; 90(8):e0015322. PubMed ID: 35862710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
